Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma.

Spaggiari D, Desfontaine V, Cruchon S, Guinchard S, Vocat A, Blattes E, Pitteloud J, Ciullini L, Bardinet C, Ivanyuk A, Makarov V, Ryabova O, Buclin T, Cole ST, Decosterd LA.

PLoS One. 2019 May 31;14(5):e0217139. doi: 10.1371/journal.pone.0217139. eCollection 2019.

2.

Synthesis of diphenoxyadamantane alkylamines with pharmacological interest.

Georgiadis MO, Kourbeli V, Ioannidou V, Karakitsios E, Papanastasiou I, Tsotinis A, Komiotis D, Vocat A, Cole ST, Taylor MC, Kelly JM.

Bioorg Med Chem Lett. 2019 Jun 1;29(11):1278-1281. doi: 10.1016/j.bmcl.2019.04.010. Epub 2019 Apr 6.

PMID:
30981579
3.

Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.

Foo CS, Lupien A, Kienle M, Vocat A, Benjak A, Sommer R, Lamprecht DA, Steyn AJC, Pethe K, Piton J, Altmann KH, Cole ST.

MBio. 2018 Oct 9;9(5). pii: e01276-18. doi: 10.1128/mBio.01276-18.

4.

Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).

Lupien A, Vocat A, Foo CS, Blattes E, Gillon JY, Makarov V, Cole ST.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00840-18. doi: 10.1128/AAC.00840-18. Print 2018 Nov.

5.

Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis.

Piton J, Vocat A, Lupien A, Foo CS, Riabova O, Makarov V, Cole ST.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00681-18. doi: 10.1128/AAC.00681-18. Print 2018 Oct.

6.

In vitro Controlled Release from Solid Pharmaceutical Formulations of two new Adamantane Aminoethers with Antitubercular Activity (I).

Vlachou M, Siamidi A, Diamantidi E, Iliopoulou A, Papanastasiou I, Ioannidou V, Kourbeli V, Foscolos AS, Vocat A, Cole ST, Karalis V, Kellici T, Mavromoustakos T.

Drug Res (Stuttg). 2017 Aug;67(8):447-450. doi: 10.1055/s-0042-121491. Epub 2017 May 30.

PMID:
28561241
7.

Rv3852 (H-NS) of Mycobacterium tuberculosis Is Not Involved in Nucleoid Compaction and Virulence Regulation.

Odermatt NT, Sala C, Benjak A, Kolly GS, Vocat A, Lupien A, Cole ST.

J Bacteriol. 2017 Jul 25;199(16). pii: e00129-17. doi: 10.1128/JB.00129-17. Print 2017 Aug 15.

8.

Discovery and Biosynthesis of Gladiolin: A Burkholderia gladioli Antibiotic with Promising Activity against Mycobacterium tuberculosis.

Song L, Jenner M, Masschelein J, Jones C, Bull MJ, Harris SR, Hartkoorn RC, Vocat A, Romero-Canelon I, Coupland P, Webster G, Dunn M, Weiser R, Paisey C, Cole ST, Parkhill J, Mahenthiralingam E, Challis GL.

J Am Chem Soc. 2017 Jun 14;139(23):7974-7981. doi: 10.1021/jacs.7b03382. Epub 2017 Jun 5.

9.

New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis.

Salina EG, Ryabova O, Vocat A, Nikonenko B, Cole ST, Makarov V.

J Infect Chemother. 2017 Nov;23(11):794-797. doi: 10.1016/j.jiac.2017.04.012. Epub 2017 May 18.

PMID:
28527650
10.

Synthesis of Adamantane Aminoethers with Antitubercular Potential.

Foscolos AS, Papanastasiou I, Tsotinis A, Kolocouris N, Foscolos GB, Vocat A, Cole ST.

Med Chem. 2017;13(7):670-681. doi: 10.2174/1573406413666170125112709.

PMID:
28124614
11.

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.

Singh V, Dhar N, Pató J, Kolly GS, Korduláková J, Forbak M, Evans JC, Székely R, Rybniker J, Palčeková Z, Zemanová J, Santi I, Signorino-Gelo F, Rodrigues L, Vocat A, Covarrubias AS, Rengifo MG, Johnsson K, Mowbray S, Buechler J, Delorme V, Brodin P, Knott GW, Aínsa JA, Warner DF, Kéri G, Mikušová K, McKinney JD, Cole ST, Mizrahi V, Hartkoorn RC.

Mol Microbiol. 2017 Jan;103(1):13-25. doi: 10.1111/mmi.13535. Epub 2016 Oct 29.

12.

The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis.

Singh V, Donini S, Pacitto A, Sala C, Hartkoorn RC, Dhar N, Keri G, Ascher DB, Mondésert G, Vocat A, Lupien A, Sommer R, Vermet H, Lagrange S, Buechler J, Warner DF, McKinney JD, Pato J, Cole ST, Blundell TL, Rizzi M, Mizrahi V.

ACS Infect Dis. 2017 Jan 13;3(1):5-17. doi: 10.1021/acsinfecdis.6b00102. Epub 2016 Sep 8.

13.

Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.

Karabanovich G, Zemanová J, Smutný T, Székely R, Šarkan M, Centárová I, Vocat A, Pávková I, Čonka P, Němeček J, Stolaříková J, Vejsová M, Vávrová K, Klimešová V, Hrabálek A, Pávek P, Cole ST, Mikušová K, Roh J.

J Med Chem. 2016 Mar 24;59(6):2362-80. doi: 10.1021/acs.jmedchem.5b00608. Epub 2016 Mar 15.

PMID:
26948407
14.

Lansoprazole is an antituberculous prodrug targeting cytochrome bc1.

Rybniker J, Vocat A, Sala C, Busso P, Pojer F, Benjak A, Cole ST.

Nat Commun. 2015 Jul 9;6:7659. doi: 10.1038/ncomms8659.

15.

The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.

Makarov V, Neres J, Hartkoorn RC, Ryabova OB, Kazakova E, Šarkan M, Huszár S, Piton J, Kolly GS, Vocat A, Conroy TM, Mikušová K, Cole ST.

Antimicrob Agents Chemother. 2015 Aug;59(8):4446-52. doi: 10.1128/AAC.00778-15. Epub 2015 May 18.

16.

Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis.

Vocat A, Hartkoorn RC, Lechartier B, Zhang M, Dhar N, Cole ST, Sala C.

Antimicrob Agents Chemother. 2015 Jul;59(7):4012-9. doi: 10.1128/AAC.00528-15. Epub 2015 Apr 20.

17.

Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion.

Rybniker J, Chen JM, Sala C, Hartkoorn RC, Vocat A, Benjak A, Boy-Röttger S, Zhang M, Székely R, Greff Z, Orfi L, Szabadkai I, Pató J, Kéri G, Cole ST.

Cell Host Microbe. 2014 Oct 8;16(4):538-48. doi: 10.1016/j.chom.2014.09.008.

18.

Assessing essentiality of transketolase in Mycobacterium tuberculosis using an inducible protein degradation system.

Kolly GS, Sala C, Vocat A, Cole ST.

FEMS Microbiol Lett. 2014 Sep;358(1):30-5. doi: 10.1111/1574-6968.12536. Epub 2014 Aug 4.

19.

Rv2466c mediates the activation of TP053 to kill replicating and non-replicating Mycobacterium tuberculosis.

Albesa-Jové D, Chiarelli LR, Makarov V, Pasca MR, Urresti S, Mori G, Salina E, Vocat A, Comino N, Mohorko E, Ryabova S, Pfieiffer B, Lopes Ribeiro AL, Rodrigo-Unzueta A, Tersa M, Zanoni G, Buroni S, Altmann KH, Hartkoorn RC, Glockshuber R, Cole ST, Riccardi G, Guerin ME.

ACS Chem Biol. 2014 Jul 18;9(7):1567-75. doi: 10.1021/cb500149m. Epub 2014 Jun 13.

20.

In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.

Zhang M, Sala C, Dhar N, Vocat A, Sambandamurthy VK, Sharma S, Marriner G, Balasubramanian V, Cole ST.

Antimicrob Agents Chemother. 2014 Jun;58(6):3217-23. doi: 10.1128/AAC.02410-14. Epub 2014 Mar 24.

21.

Towards a new combination therapy for tuberculosis with next generation benzothiazinones.

Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, Hartkoorn RC, Ryabova OB, Vocat A, Decosterd LA, Widmer N, Buclin T, Bitter W, Andries K, Pojer F, Dyson PJ, Cole ST.

EMBO Mol Med. 2014 Mar;6(3):372-83. doi: 10.1002/emmm.201303575. Epub 2014 Feb 5.

22.

[Renovascular prognosis of preeclampsia on the mother and the child].

Dayer ML, Vocat A, Ditisheim A, Pechère-Bertschi A.

Rev Med Suisse. 2013 Sep 11;9(397):1628-30, 1632. French.

PMID:
24073474

Supplemental Content

Support Center